Urologix, Inc.
ULGX
$0.0001
$0.000.00%
| 03/31/2015 | 12/31/2014 | 09/30/2014 | 06/30/2014 | 03/31/2014 | |
|---|---|---|---|---|---|
| Revenue | -16.71% | -19.11% | -20.04% | -21.29% | -18.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.71% | -19.11% | -20.04% | -21.29% | -18.24% |
| Cost of Revenue | -40.77% | -19.57% | -18.59% | -14.81% | 21.94% |
| Gross Profit | 58.97% | -18.57% | -21.58% | -27.44% | -59.85% |
| SG&A Expenses | -39.89% | -46.65% | -48.70% | -37.86% | -29.93% |
| Depreciation & Amortization | -42.86% | -22.73% | 0.00% | -11.54% | 7.69% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.26% | -33.00% | -34.26% | -28.06% | -8.83% |
| Operating Income | 89.66% | 86.28% | 79.42% | 58.21% | -22.74% |
| Income Before Tax | 78.80% | 66.98% | 67.32% | -180.02% | -66.60% |
| Income Tax Expenses | -- | -75.00% | -58.33% | -82.35% | 5.88% |
| Earnings from Continuing Operations | 79.03% | 67.10% | 67.24% | -182.68% | -65.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 79.03% | 67.10% | 67.24% | -182.68% | -65.57% |
| EBIT | 89.66% | 86.28% | 79.42% | 58.21% | -22.74% |
| EBITDA | 96.85% | 97.84% | 89.45% | 67.37% | -28.39% |
| EPS Basic | 79.49% | 67.91% | 68.03% | -177.68% | -62.16% |
| Normalized Basic EPS | 79.42% | 70.21% | 68.18% | 50.89% | -24.30% |
| EPS Diluted | 75.00% | 60.86% | 68.03% | -183.14% | -60.00% |
| Normalized Diluted EPS | 79.42% | 70.21% | 68.18% | 50.89% | -24.30% |
| Average Basic Shares Outstanding | 2.40% | 2.53% | 2.22% | 1.87% | 2.03% |
| Average Diluted Shares Outstanding | 2.40% | 2.53% | 2.22% | 1.87% | 2.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
